About: SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Creator	Zhang, Yi Baric, Ralph Shi, Wei Wang, Nianshuang Schäfer, Alexandra Kong, Wing-Pui Wang, Lingshu Gully, Kendra West, Ande Dinnon, Kenneth Louder, Mark Leung, Kwanyee Carfi, Andrea Bahl, Kapil Abiona, Olubukola Minai, Mahnaz Liu, Catherine Mascola, John Denison, Mark Himansu, Sunny Bock, Kevin Chappell, James Fritch, Ethan Leist, Sarah Mclellan, Jason Morabito, Kaitlyn Stewart-Jones, Guillaume Doria-Rose, Nicole Narayanan, Altaras, Nedim Bennett, Hamilton Chang, Lauren Corbett 1#, Kizzmekia Dipiazza, Anthony Elbashir, Sayda Garcia-Dominguez, Dario Gillespie, Rebecca Hutchinson, Geoffrey Loomis, Rebecca Ma, Lingzhi Martinez, David Metkar, Mihir Moore, N Nagata, M Phung, Emily Presnyak, Vlad Renzi, Isabella Ruckwardt, Tracy Schmidt, Stephen Seyhan, Shaw, Christine Stevens, Woods, Angela Yang, Eun
Source	BioRxiv; Medline; WHO
abstract	A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1101/2020.06.11.145920
bibo:pmid	32577634
has license	biorxiv
sha1sum (hex)	687ad44e3b56c0991c9d723e62b871ceff27ca68
schema:url	https://doi.org/10.1101/2020.06.11.145920
resource representing a document's title	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
has PubMed identifier	32577634
schema:publication	bioRxiv
resource representing a document's body	covid:687ad44e3b56c0991c9d723e62b871ceff27ca68#body_text
is schema:about of	named entity 'expression' named entity 'sequences' named entity 'mice' named entity 'expressing' named entity 'structures' named entity 'mRNA vaccine' named entity 'directed' named entity 'mRNA' named entity 'Phase 3' named entity 'immunogen' named entity 'public health crisis' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'CD8 T cell' named entity 'mice' named entity 'Vaccine' named entity 'control' named entity 'mice' named entity 'vaccine' named entity 'mRNA' named entity 'mRNA' named entity 'immunopathology' named entity 'mRNA' named entity 'vaccine' named entity 'Th1/Th2' named entity 'lungs' named entity 'mice' named entity 'lung' named entity 'endotoxin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software